Millennium Begins Clinical Trials for its First Genomically- Designed Drug | GenomeWeb

SAN FRANCISCO, Nov. 28 – Millennium Pharmaceuticals on Tuesday announced it had begun Phase I clinical trials for its first molecule directed against a genomically- derived target for metabolic disease.

The compound, called MLN4760, was synthesized by Millennium and was designed with the hope of providing a treatment for obesity. Millennium, based in Cambridge, Mass., partnered with Abbott Park, Ill.-based Abbott Laboratories in the development of the drug.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: global genetic diversity map, and more.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.